MedPath

Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).

Conditions
C10.114.375.500
Registration Number
NCT04028232
Lead Sponsor
University Hospital, Caen
Brief Summary

Background: In comparison to general population, persons with Multiple Sclerosis have a higher risk to premature death with an estimate reduced life expectancy from 7 to 14 years. However, risk factors of mortality in MS are not well identified and well known. Following the example of studies carry on cancers survival, socioeconomic status (SES) may have an influence on survival in MS.

Objective: The main objective of ECOVIMUS is to estimate net survival according to SES using the European Deprivation Index as a proxy and other major covariates (gender, initial clinical phase and years of disease onset).

Methods: In order to answer to our main objective, we will use a retrospective cohort of MS patients with a medical follow-up in one of the 18 centers included in SURVIMUS II, with a MS onset between 1960 and 2015 and with an informed vital at the date of December 31st, 2015.

The ecological score of deprivation EDI will be used as a proxy of the socioeconomic status and will be attributed from the geolocalisation to patient's residence address. Net survival is directly associated to the notion of "mortality in excess". This mortality will be estimated comparing the observed mortality in MS patients to mortality in the general population. The advantage of this methodological approach is that cause of death is not needed.

Statistical analysis: The influence of socioeconomic status on the excess of mortality will be estimated thanks to a parametric multivariate model of excess rate mortality. This model will be adjusted on other major covariates (gender, age at disease onset, and initial clinical phase) and will include potential complex effects as non-linearity, non-proportionality and interactions.

Expected results: We expect to highlight some differences of net survival in MS patients according to socioeconomic group as it was already shown in cancers. This study will complete information on factors of mortality excess in MS and knowledge on socioeconomic inequalities encountered all along MS disease course.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30000
Inclusion Criteria
  • all patients registered in 17 selected French OFSEP centres with core dataset with a sufficient level of data
  • Diagnosis a of definite or probably MS according to Poser or McDonald criteria. With an MS onset date between January 1st, 1960 and December 31st, 2015.
  • With a postal residence address well informed in the OFSEP database.
Exclusion Criteria
  • MS patients with less than one year's disease duration by the study end will be excluded.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Excess mortality survivalFrom date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.

Net survival is defined as the probability of death in a hypothetical setting where the cause of interest (in our case MS) would be the only possible cause of death. It is directly linked to the concept of the "excess mortality due to the studied disease". Net survival can be calculated according to two settings, either the estimator of survival can be calculated from death due to MS while cause of death are known, either it can be calculated from the excess of mortality due to MS compared to the mortality of the general population obtained from mortality table of the generable population.

Secondary Outcome Measures
NameTimeMethod
European Deprivation Index (EDI) proxy of Socio-Economic StatusFrom date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.

The EDI Score is a combination of weighted ecological variates and is available for each 'IRIS area' (Ilots regroupés pour l'Information Statistique). An IRIS area represents the smallest geographical entity for which census data are available in France.

The geolocation of each individual address, according to latitude and longitude coordinates, is performed with the system of geographical information (SGI) ARGIS® 10.5. This point of geolocation is correlated to the IRIS area and then an EDI score can be attributed to patients registered in the database. The EDI score can be categorized into quintiles.

Distance to MS expert care centerFrom date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.

Distance in kilometer by road transport from residence place to MS expert care center

Trial Locations

Locations (18)

University Hospital Center of CAEN

🇫🇷

Caen, Normandy, France

University Hospital of Besancon

🇫🇷

Besançon, France

University Hospital of Bordeaux

🇫🇷

Bordeaux, France

University Hospital Centre of Caen

🇫🇷

Caen, France

University Hospital of Clermont Ferrand

🇫🇷

Clermont-Ferrand, France

University Hospital of Dijon

🇫🇷

Dijon, France

University Hospital of Lille

🇫🇷

Lille, France

University Hospital of Lyon

🇫🇷

Lyon, France

University Hospital of Marseille

🇫🇷

Marseille, France

University Hospital of Montpellier

🇫🇷

Montpellier, France

Scroll for more (8 remaining)
University Hospital Center of CAEN
🇫🇷Caen, Normandy, France
Gilles-Louis DEFER, Professor
Contact
0033231064617
defer-gi@chu-caen.fr
Floriane CALOCER, PharmD/PhD
Contact
0033231064617
calocer-fl@chu-caen.fr
Eric BERGER, Pr
Principal Investigator
Claudine LEBRUN-FRENAY, Pr
Principal Investigator
David BRASSAT, Pr
Principal Investigator
David LAPLAUD, Pr
Principal Investigator
Jérôme DE SEZE, Pr
Principal Investigator
Bruno BROCHET, Pr
Principal Investigator
Gilles DEFER, Pr
Principal Investigator
Gilles EDAN, Pr
Principal Investigator
Giovanni CASTELNOVO, Pr
Principal Investigator
Jean PELLETIER, Pr
Principal Investigator
Jean-Philippe CAMDESSANCHE, Pr
Principal Investigator
Pierre CLAVELOU, Pr
Principal Investigator
Pierre LABAUGE, Pr
Principal Investigator
Sandra VUKUSIC, Pr
Principal Investigator
Thilbault MOREAU, Pr
Principal Investigator
Marc DEBOUVERIE, Pr
Principal Investigator
Patrick VERMERSH, Pr
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.